BUY Mankind Pharma Limited — Jay Thakkar, ICICI Securities
byJay Thakkar, ICICI SecuritiesHorizon: NA (inferred Swing (≤2wk))23 Jul 2026via Business Today
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Mankind Pharma Q1 profit rises 30%, margins expand on strong domestic business
NewsCnbc-Tv18·30 Jul · 5d ago
Mankind Pharma announced strong Q1FY27 financial results with a 13% YoY revenue growth to INR 4,031 Crore and a 25% YoY EBITDA growth to INR 1,060 Crore. PAT grew by 29% YoY. The company highlighted d
BSE · Company Update·30 Jul · 5d ago
Mankind Pharma completes sale of Broadway Hospitality stake for ₹49 crore
NewsGoogle News·27 Jul · 1w ago
2 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·7 Jul · 4w ago
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·30 Jul · 6d ago
Mankind Pharma Limited's Board approved the divestment of its 100% stake in Broadway Hospitality Services Private Limited and the incorporation of a wholly-owned subsidiary in Netherlands for R&D inve
NSE · Acquisition·11 Jul · 4w ago
Mankind Pharma Ltd's Board approved the incorporation of a wholly owned subsidiary in the Netherlands.
BSE · Company Update·11 Jul · 4w ago
Mankind Pharma Limited's Board approved the divestment of its 100% stake in Broadway Hospitality Services Private Limited and the incorporation of a wholly owned subsidiary in Netherlands for R&D inve
NSE · Outcome of Board Meeting·11 Jul · 4w ago
Mankind Pharma's Board approved the divestment of its 100% stake in Broadway Hospitality Services Private Limited and the incorporation of a wholly-owned subsidiary in Netherlands for R&D investments.
BSE · Others·11 Jul · 4w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Mankind Pharma
- BUY — Ashish Kyal, Waves Strategy Advisors7 Oct 2026 · Next day · target ₹2,550 · SL hit
- BUY — Swati Hotkar, Nirmal Bang Securities7 Oct 2026 · Same day · target ₹2,580 · Expired
- SELL — Macquarie7 Oct 2026 · ~1 year · target ₹2,200 · Active
- BUY — Vishvesh Chauhan, ChaseAlpha30 Sept 2026 · ~2 weeks · target ₹2,640 · SL hit
- BUY — Raja Venkatraman30 Sept 2026 · ~3 months · target ₹2,800 · SL hit
More from Jay Thakkar, ICICI Securities
- BUY Lloyds Metals And Energy22 Oct 2026 · ~1 year · target ₹1,980 · Active
- BUY Varun Beverages22 Sept 2026 · ~2 weeks · target ₹440 · SL hit
- BUY Power Grid Corporation of India10 Sept 2026 · ~2 weeks · target ₹285 · Expired
- BUY Railtel Corporation Of India19 Aug 2026 · ~1 year · target ₹325 · SL hit
- BUY National Aluminium Company6 Aug 2026 · ~2 weeks · target ₹420 · Target hit

